<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546648</url>
  </required_header>
  <id_info>
    <org_study_id>POISE3034</org_study_id>
    <nct_id>NCT02546648</nct_id>
  </id_info>
  <brief_title>PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study</brief_title>
  <acronym>POISE-3</acronym>
  <official_title>PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study (POISE-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A placebo-controlled, factorial trial to assess the impact of rosuvastatin and tranexamic&#xD;
      acid (TXA) in patients undergoing noncardiac surgery who are at risk of a perioperative&#xD;
      cardiovascular event.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The POISE-3 pilot is a randomized controlled trial of 100 patients with, or at risk of,&#xD;
      atherosclerotic disease who are undergoing noncardiac surgery. Utilizing a partial factorial&#xD;
      design, the POISE-3 pilot will determine the effect of rosuvastatin versus placebo and TXA&#xD;
      versus placebo in the perioperative setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative intervention discontinuation</measure>
    <time_frame>Postoperative day 1 to 30.</time_frame>
    <description>Interruption of the intervention longer than 24 hours within the first 10 days postoperatively, and longer than 48 hours from postoperative day 10 to 30.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Postoperative day 1.</time_frame>
    <description>Change in preoperative hemoglobin to the morning hemoglobin recorded on day 1 after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Postoperative day 30.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>Postoperative day 30.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A composite of vascular mortality and non-fatal: myocardial infarction, stroke, cardiac arrest, pulmonary embolus, deep venous thrombosis, life threatening bleeding, major bleeding.</measure>
    <time_frame>Postoperative day 30.</time_frame>
    <description>Event composite</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Outcomes for Rosuvastatin assessed by Statin induced myopathy</measure>
    <time_frame>Postoperative day 30.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes for Tranexamic Acid assessed by Seizure, pulmonary emboli, deep venous thrombosis, vascular mortality</measure>
    <time_frame>Postoperative day 30.</time_frame>
    <description>myocardial infarction, stroke, non-fatal cardiac arrest, and cardiac revascularization procedure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atherosclerotic Disease</condition>
  <condition>Perioperative Bleeding</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid vs. matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin vs. matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid vs. matching placebo</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Placebo</intervention_name>
    <arm_group_label>Tranexamic Acid vs. matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin or matching placebo</intervention_name>
    <description>Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.</description>
    <arm_group_label>Rosuvastatin vs. matching placebo</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. undergoing noncardiac surgery&#xD;
&#xD;
          2. &gt;45 years of age&#xD;
&#xD;
          3. expected to require at least an overnight hospital admission after surgery; AND&#xD;
&#xD;
          4. have a preoperative NT-pro-BNP measurement &gt;100 ng/mL; OR&#xD;
&#xD;
          5. if a preoperative NT-pro-BNP measurement is not available, then the patient must&#xD;
             fulfill 1 or more of the following 5 criteria:&#xD;
&#xD;
               -  history of coronary artery disease&#xD;
&#xD;
               -  history of peripheral vascular disease&#xD;
&#xD;
               -  history of stroke&#xD;
&#xD;
               -  undergoing major vascular surgery&#xD;
&#xD;
               -  have any 3 of the following 9 risk criteria:&#xD;
&#xD;
                    -  undergoing major surgery&#xD;
&#xD;
                    -  history of congestive heart failure&#xD;
&#xD;
                    -  history of a transient ischemic attack&#xD;
&#xD;
                    -  diabetic and currently taking an oral hypoglycemic agent or insulin&#xD;
&#xD;
                    -  age &gt;70 years&#xD;
&#xD;
                    -  hypertension&#xD;
&#xD;
                    -  serum creatinine &gt; 175 umol/L (&gt;2.0 mg/dl)&#xD;
&#xD;
                    -  history of smoking within 2 years of surgery&#xD;
&#xD;
                    -  undergoing emergent/urgent surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. planned use of systemic Tranexamic Acid during surgery&#xD;
&#xD;
          2. hypersensitivity or known allergy to TXA&#xD;
&#xD;
          3. creatinine clearance &lt;30 mL/min (MDRD)&#xD;
&#xD;
          4. history of seizure disorder&#xD;
&#xD;
          5. history of venous thromboembolism&#xD;
&#xD;
          6. acute arterial thrombosis&#xD;
&#xD;
          7. no preoperative measurement of hemoglobin&#xD;
&#xD;
          8. subarachnoid hemorrhage within the past 30 days&#xD;
&#xD;
          9. hematuria caused by diseases of the renal parenchyma&#xD;
&#xD;
         10. previously enrolled in POISE-3 pilot trial&#xD;
&#xD;
         11. not consenting to participate in POISE-3 pilot trial prior to surgery&#xD;
&#xD;
        Patients meeting any of the following criteria will be excluded from the&#xD;
        Rosuvastatin/Placebo arm:&#xD;
&#xD;
          1. preoperative treatment with a statin or a non statin lipid lowering drug or&#xD;
             ciclosporin during the 48 hours before surgery&#xD;
&#xD;
          2. hypersensitivity or known allergy to Rosuvastatin&#xD;
&#xD;
          3. pre-disposed factors for myopathy or rhabdomyolysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Khan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

